Digital Twins: When AI drives progress for the pharmaceutical industry

In its inaugural edition, Servier digital magazine, Insights, features Aitia’s Gemini Digital Twins in its “Science Calling” section. The conversion of causal AI and Gemini Digital Twins with industrial expertise holds the potential to significantly expedite R&D phases and streamline the identification of new targets. In May 2023, Aitia and Servier inked a multi-year agreement […]

Servier and Aitia Announce a New Collaboration Focused on Parkinson’s Disease

Aitia‘s Gemini Digital Twins will help identify subpopulations of patients who could respond favorably to Servier’s LRRK2 in development treatment Suresnes (France), 08 January 2024 – Servier, an independent international pharmaceutical group, and Aitia, the leader in the application of causal AI and Digital Twins, have strengthened today their partnership by signing a new contract […]

Servier Will Apply Aitia’s Gemini Digital Twins to Parkinson’s Drug

Spotlight on our joint effort with Servier, strengthening our partnership by entering a new collaboration focused on neuroscience. The aim of this cooperation is to leverage Aitia’s Gemini Digital Twins to identify patients most likely to respond positively to Servier’s Leucine-Rich-Repeat-Kinase 2 inhibitor (LRRK2i) in development treatment for Parkinson’s disease. Read the full article on […]

Partner of Choice: Aitia and Servier Revolutionize the Landscape of Pancreatic Cancer Treatment

Spotlight on our joint effort with Servier to advance the discovery and simulation of drugs for Pancreatic Cancer. This strategic partnership aims to delve into the intricate mechanisms of this complex disease, with the goal of expediting the development of innovative therapies for individuals affected by pancreatic cancer. Read what Servier had to say about […]

Charles River and Aitia Join Forces to Harness AI and Gemini Digital Twins in Advancing Neurodegenerative and Oncology Research

Charles River Laboratories has entered into an agreement granting Aitia access to its artificial intelligence-powered drug solution platform. The objective is to expedite the development of multiple therapy programs targeting neurodegenerative diseases and oncology. Read more on the recent collaboration between Charles River and Aitia, in Fierce Biotech article. Full article available here.

Servier and Aitia Mobilize AI and Digital Twins to Treat Pancreatic Cancer

The French pharmaceutical group Servier and Aitia announced on May 17th a multi-year partnership agreement for the discovery and simulation of drugs in pancreatic cancer. It is based on the combination of Servier’s expertise in preclinical trials with Aitia’s technology, which is based on artificial intelligence and Gemini Digital Twins. Read more on the latest […]

Colin Hill Keynote at Servier Paris-Saclay R&D Institute in France

On July 20th, we had the privilege to visit the cutting-edge Servier Paris-Saclay R&D Institute in France, where our CEO, Colin Hill delivered a keynote titled: “Why AI and Digital Twins will Drive the Discovery and Development of the Next Generation of Breakthrough Drugs“. The open conference was a remarkable display of Servier’s dedication to foster a collaborative […]

Servier Doubles Up on Digital Twin Alliance with Aitia

The new project will focus on pancreatic cancer, and builds on a collaboration in the blood cancer multiple myeloma that was started by the two companies last year. Read more on the latest collaboration between Servier and Aitia, in Pharmaphorum article. Full article here. Picture Credit: Pharmaphorum